Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Schenkel

Allergy & Immunology Bethlehem, PA Medical Doctor

NPI 1306958939 CMS profile 194854

3101 Emrick Blvd, Ste 211, Bethlehem, PA 18020

Open in the dashboard

General payments

$844,555

1,568 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$61 paid to institutions, not to them · program year 2021

Through program year 2025, Eric Schenkel of Bethlehem, PA is reported in the CMS Open Payments database as having received $844,555 across 1,568 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $61 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74,238 90
2024 General $156,251 208
2023 General $170,851 317
2022 General $150,756 260
2021 General $81,665 199
2020 General $56,402 173
2019 General $154,391 321

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Schenkel
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Eric Schenkel were reported at $74,238. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Eric Schenkel Allergy & Immunology median Middle half National median
2019 $154,391 $594 $163–$1,512 $163
2020 $56,402 $426 $106–$1,233 $114
2021 $81,665 $638 $157–$1,708 $132
2022 $150,756 $790 $205–$1,961 $149
2023 $170,851 $852 $220–$2,147 $160
2024 $156,251 $865 $203–$2,267 $164
2025 $74,238 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $306,232 454 payments
  2. Genzyme Corporation $203,747 236 payments
  3. AstraZeneca Pharmaceuticals LP $137,912 277 payments
  4. GlaxoSmithKline, LLC. $73,287 126 payments
  5. OptiNose US, Inc. $62,818 102 payments
  6. ALK-Abello, Inc $18,394 41 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $14,280 48 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $7,637 30 payments
  9. Merck Sharp & Dohme Corporation $6,256 11 payments
  10. Pharming Healthcare, Inc. $4,281 15 payments
  11. Other $9,710 228 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $651,223 294 payments
  2. Travel and Lodging $111,762 316 payments
  3. Consulting Fee $38,051 21 payments
  4. Food and Beverage $34,673 928 payments
  5. Honoraria $8,700 4 payments
  6. Education $147 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $279,729 426 payments
  2. DUPIXENT Immunology $208,562 288 payments
  3. NUCALA $68,660 78 payments
  4. Xhance $62,818 102 payments
  5. TEZSPIRE $46,310 58 payments
  6. FASENRA $39,965 76 payments
  7. AIRSUPRA $32,296 51 payments
  8. DUPIXENT Immunology $26,701 39 payments
  9. DUPIXENT Immunology And Inflammation $23,337 25 payments
  10. Odactra $17,422 38 payments
  11. Other $47,678 499 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,119

Median for Allergy/ Immunology: 449

Drug cost

$370,354

Median for Allergy/ Immunology: $169,700

Branded share of claims

52.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 22 $120,175
Breo Ellipta Fluticasone/Vilanterol Brand 93 $66,195
Arnuity Ellipta Fluticasone Furoate Brand 100 $40,573
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $35,899
Qvar Redihaler Beclomethasone Dipropionate Brand 59 $24,763
Xhance Fluticasone Propionate Brand 19 $19,099
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 21 $17,308
Asmanex Mometasone Furoate Brand 21 $7,177
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 25 $5,547
Epinephrine Generic 25 $5,294

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$126,733

Medicare's payments for the services billed

Medicare patients

205

Average age 73

Services billed

7,536

133 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Chronic kidney disease 24%
Diabetes 22%
Osteoporosis 22%
Depression 19%
Ischemic heart disease 18%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$82,074 22 —
Xhance
$26,555 19 —
AIRSUPRA
$25,066 — —
TEZSPIRE
$16,979 — —
NUCALA
$1,625 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

1,568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record